SYBLEU (SYBE) Stock Price

SYBLEU Price

NYSE·CLOSED
0.05
​
Market closed

Over the last 2 years SYBLEU grew revenue by 68.9% annually, reaching 11,700.00 USD. For SYBLEU, the net margin of -1,541.0% is up versus -2,485.4% a few years ago.

SYBLEU stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SYBLEU business model & stock analysis

SYBLEU Inc develops regenerative medical applications focused on therapies for human and animal health, medical devices, and clinical diagnostics. The company generates revenue through the sale or licensing of its developed applications after completing Phase I or Phase II clinical trials, or by advancing them to Phase III trials. It also develops disposable medical devices and explores artificial intelligence and machine learning applications in clinical diagnostics. SYBLEU Inc targets the healthcare sector with its innovative medical solutions. The firm's primary products include therapies for human and animal health, medical devices, and clinical diagnostics. It also develops drugs for treating cancer in companion animals, leveraging artificial intelligence and machine learning in its diagnostic processes. SYBLEU Inc's business model relies on advancing its applications through clinical trials to either secure licensing deals or commercialize its products directly. SYBLEU Inc's target market segments are healthcare providers, veterinary clinics, and medical device manufacturers seeking innovative regenerative therapies and diagnostic tools. The company's focus on companion animal cancer treatments and AI-enhanced diagnostics positions it within specialized segments of the medical industry. Its development of disposable medical devices further expands its reach into the broader healthcare market.

Frequently asked questions about SYBLEU

Converted at the current exchange rate, the SYBLEU share trades at 0.05 EUR (0.05 USD).

The revenue cannot currently be calculated for SYBLEU.

The profit cannot currently be calculated for SYBLEU.

The P/E ratio cannot be calculated for SYBLEU at the moment.

The P/S cannot be calculated for SYBLEU currently.

The Eulerpool Quality Score for SYBLEU is 4/10.

The ISIN of SYBLEU is US87114K1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of SYBLEU is SYBE. The ticker symbol is used to trade SYBLEU shares on the stock exchange.

Fair ValueTerminal
0.05 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Currency
USD
Initial public offering
Mar 9, 2023
ISIN
US87114K1051
Cusip
87114K105
Market capitalization
5.47 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-142.53 %
Last updated Nov 19, 2026, 3:51 AM

SYBLEU Peer Group

SYBLEU FIGI

SYBE:US · BBG00X71LG35SYBE:PQ · BBG01FSR8RP0SYBE:UV · BBG01FSR8RQ9

All fundamentals and in-depth analysis of SYBLEU

Our stock analysis for SYBLEU stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SYBLEU. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.